My watch list
my.bionity.com  
Login  

618 Current news from israel

rss
matching the following criteria

Lonza Continues to Make Measurable Progress in Its Transformation

23-Jan-2015

In 2014 Lonza delivered expected CORE EBIT growth of 11% in constant exchange rates (CER) (+9% in reported currency), compared with 2013. Lonza’s overall results confirm the updated guidance communicated during the third-quarter update. Both of Lonza’s segments – Specialty Ingredients and ...

more

Damaged DNA amplified

20-Jan-2015

In the majority of cases, the onset of cancer is characterised by a minor change in a person's genetic material. A cell's DNA mutates in a particular area to the extent that the cell no longer divides in a controlled manner, but begins to grow uncontrollably. In many cases, this type of genetic ...

more

Evolva and L’Oréal reach first milestone in cosmetics ingredient project

09-Jan-2015

Evolva Holding SA announced the successful completion of the first part of its R&D collaboration with L’Oréal. The parties have agreed to move into the next phase of the multi-year programme. Under this collaboration, which started in February 2014, Evolva and L’Oréal are applying Evolva’s ...

more

Cytos exclusively licenses its VLP platform for the treatment of hepatitis B infections to OnCore Biopharma

08-Jan-2015

Cytos Biotechnology Ltd. announced that it executed an exclusive license agreement granting OnCore Biopharma, Inc. access to Cytos’ clinically validated virus like particle (VLP) platform for the use in the treatment and prevention of hepatitis B viral infections. Cytos also granted an option for ...

more

Smartphone thumb skills are altering our brains

29-Dec-2014

Typing, sweeping, swiping – Smartphone users have nimble thumbs and forefingers. However, it is not only finger dexterity that the daily use of mobile technology develops. As researchers from the Universities of Zurich and Fribourg demonstrate, it also alters the brain. The cortex quickly adapts ...

more

Anergis Granted U.S. Patent for Ragweed Allergy Vaccine AllerR

22-Dec-2014

Anergis announced that it received a notice of allowance from the US patent authorities for its patent covering composition and methods of use of its ragweed allergy product AllerR. AllerR is based on Anergis´ unique Contiguous Overlapping Peptide (COP) platform. COPs are pharmaceutical-grade, ...

more

image description
Trigger mechanism for recovery after spinal cord injury revealed

22-Dec-2014

After an incomplete spinal cord injury, the body can partially recover basic motor function. So-called muscle spindles and associated sensory circuits back to the spinal cord promote the establishment of novel neuronal connections after injury. This circuit-level mechanism behind the process of ...

more

Evolva completes Allylix acquisition

17-Dec-2014

Evolva Holding SA announces the completion of the acquisition of Allylix, Inc., after which Allylix will be a wholly-owned subsidiary of Evolva. This acquisition was announced on 18 November 2014. Evolva will acquire Allylix in return for an overall consideration of 46 million newly-issued Evolva ...

more

image description
Why tumours exhibit fatty degeneration

16-Dec-2014

In cases of clear cell renal cell carcinoma – the most common type of renal cell carcinoma – the cancer cells become fatty. The reasons for this were long unclear, but ETH researchers have now found the cause: important cell structures in lipometabolism degrade more rapidly. In kidney cancer and ...

more

Orphan Drug Status Granted to Vesimune for Bladder Cancer

10-Dec-2014

Telormedix announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Vesimune for the treatment of carcinoma in situ (CIS) in the bladder.The FDA grants orphan drug status to products for rare diseases and defines a rare disease as one with a prevalence of ...

more

Page 1 From 62
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE